Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III StudyRobert J. Motzer, Theodore Stewart Gourdin, Camillo Porta et al.|Journal of Clinical Oncology|2024Cited by 170
Discontinuing VEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC).Guillermo de Velasco, Toni K. Choueiri, James Brugarolas et al.|Journal of Clinical Oncology|2016Cited by 3
First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).José Manuel Ruiz Morales, Daniel Yick Chin Heng, J. Connor Wells et al.|Journal of Clinical Oncology|2016Cited by 1
Change in International mRCC Database Consortium (IMDC) prognostic category and implications for efficacy of second-line targeted therapy.Ian D. Davis, Daniel Yick Chin Heng, Wanling Xie et al.|Journal of Clinical Oncology|2016Cited by 0